Target intelligence / Profile preview

Solute carrier family 41 member 3 (SLC41A3)

Target
SLC41A3
Molecular classification
Transporter, Solute carrier protein, Magnesium:sodium antiporter[2][4][1]
01

Overview

Solute carrier family 41 member 3 (SLC41A3) is a transmembrane protein predominantly localized to the inner mitochondrial membrane, where it acts as a magnesium:sodium antiporter, exporting magnesium ions from mitochondria in a sodium-dependent manner[1][2][5]. SLC41A3 is essential for maintaining intracellular magnesium homeostasis, with highest expression in the central nervous system and kidney distal convoluted tubule[1][3]. It is upregulated in response to dietary magnesium deficiency and has been identified as an oncogenic factor and potential biomarker in liver hepatocellular carcinoma, correlating with advanced disease stage and poor prognosis[2]. Knockout models show that loss of SLC41A3 leads to neurological symptoms such as ataxia, highlighting its importance in nervous system function[1][4]. Despite significant functional evidence, no clinically approved drugs directly target SLC41A3 to date, and its broad cation transport properties suggest a potential for wide-ranging physiological effects[1][2][4].

Other names
SLC41A1-L2FLJ20473SLC41A1-like 2solute carrier family 41 member 3SLC41A3[2][7]
02

Mechanism of action

Na+-dependent and temperature-sensitive magnesium efflux from the mitochondrial inner membrane Functions as a magnesium:sodium antiporter facilitating export of Mg2+ in exchange for Na+[1][2][5]

03

Biological functions

Mitochondrial magnesium ion transmembrane transportMaintenance of intracellular magnesium homeostasisCellular ion balance and energy metabolismUnspecific cation channel activityBroad cation permeability (magnesium, sodium, possibly others)[1][2][3][5]
04

Disease associations

Cancer (notably liver hepatocellular carcinoma)[2]Neurological/behavioral abnormalities in model organisms (ataxia in knockout mice)[1][4]Potential role in magnesium deficiency/hypomagnesemia[3]
05

Safety considerations

Potential for disrupted magnesium homeostasis if SLC41A3 function is excessively inhibited or lost, which could contribute to neurological dysfunction or metabolic imbalance[1][4]
06

Biomarkers

High SLC41A3 expression is a potential biomarker for liver hepatocellular carcinoma progression and poor prognosis[2]

Beyond the preview

Go deeper on Solute carrier family 41 member 3 (SLC41A3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solute carrier family 41 member 3 (SLC41A3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call